natgillin/translations-raw huggingface dataset:
CsA levels require progressive dose adjustment using therapeutic medicinal product monitoring.
Ravni CsA zahtevajo postopno prilagajanje odmerka ob spremljanju terapevtskih učinkov zdravila.
Talk to your doctor if you are going to take both CRIXIVAN and ritonavir.
Pogovorite se z zdravnikom, če boste jemali obe zdravili, CRIXIVAN in ritonavir.
Indinavir did not have any mutagenic or genotoxic activity in studies with or without metabolic activation.
Indinavir ni imel nikakršne mutagene ali genotoksične aktivnosti v raziskavah s presnovno aktivacijo ali brez nje.
There are no data concerning the penetration of indinavir into the central nervous system in humans.
Glede prehoda indinavirja v centralni živčni sistem pri človeku ni podatkov.
Autoimmune disorders may occur many months after the start of treatment.
Avtoimune bolezni se lahko pojavijo več mesecev po začetku zdravljenja.
• tacrolimus, ciclosporin - used mainly after organ transplantation
• takrolimus, ciklosporin - večinoma se uporablja po presaditvi organa
Haemophiliac patients should therefore be made aware of the possibility of increased bleeding.
Bolnike s hemofilijo je zato treba seznaniti z možnostjo povečanja pojava krvavitev.
Do not use this medicine after the expiry date which is stated on the bottle or carton after ‘EXP'.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki ali škatli poleg oznake "Uporabno do".
Very common (≥ 1/10); Common (≥ 1/100 to  1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥ 1/10,000 to  1/1,000); Very rare (< 1/10,000); not known (cannot be estimated from the available data).
Zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
If you notice bleeding or if you feel weak, talk to your doctor straight away.
Če opazite krvavitve ali se počutite šibki, se takoj posvetujte z zdravnikom.
This includes medicines obtained without a prescription, including herbal medicines.
To velja tudi za zdravila, ki ste jih dobili brez recepta in zdravila rastlinskega izvora.
No significant difference in exposure was seen when the regimen was given with a high-fat meal.
Nobenih pomembnih razlik v izpostavljenosti ni bilo opaziti pri dajanju zdravila z obroki z visoko vsebnostjo maščob.
The relevance of the findings to humans is likely limited.
Povezava teh odkritij s človekom je precej omejena.
HIV Transmission
Prenos virusa HIV
Combination not recommended
Kombinacija ni priporočljiva.
It is not known whether CRIXIVAN is harmful to an unborn baby when taken by a pregnant woman.
Ni znano, ali je zdravilo CRIXIVAN, če ga jemlje noseča ženska, škodljivo za nerojenega otroka.
CRIXIVAN helps to:
Zdravilo CRIXIVAN pomaga:
• oral contraceptive medicines (‘The Pill') containing norethindrone or ethinyl estradiol
• zdravila za kontracepcijo ('tabletka'), ki vsebujejo noretindron ali etinilestradiol
Common (affects less than 1 in 10 people):
Pogosti (pojavijo se pri manj kot 1 od 10 bolnikov):
Also look at the Package Leaflet for ritonavir.
Prav tako poglejte navodilo za uporabo za ritonavir.
Dose adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered.
Pri midazolamu je treba razmisliti o prilagajanju odmerka, predvsem če se da več kot enkratni odmerek midazolama.
• Swallow the capsules whole with a drink of water, skimmed or low fat milk, juice, tea or coffee.
• Pogoltnite cele kapsule skupaj z vodo, posnetim mlekom ali mlekom z nizko vsebnostjo maščob, sokom, čajem ali kavo.
If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.
Če pri takih bolnikih pride do dokazanega poslabšanja jetrne bolezni, je treba razmisliti o začasni ali dokončni prekinitvi zdravljenja.
Do not take CRIXIVAN:
Ne jemljite zdravila CRIXIVAN:
Dose adjustment of warfarin may be required.
Morda bo potrebna prilagoditev odmerka varfarina.
It is not known whether indinavir is dialyzable by peritoneal or haemodialysis.
Ni znano, ali se indinavir dializira s peritonealno dializo ali hemodializo.
CRIXIVAN may not do these things in all patients.
Možno pa je, da zdravilo CRIXIVAN teh učinkov nima pri vseh bolnikih.
If you notice any of these signs, talk to your doctor.
Če opazite katerega od teh znakov, se posvetujte z zdravnikom.
Data from a steady state study in healthy volunteers indicate that there is a diurnal variation in the pharmacokinetics of indinavir.
Podatki iz raziskave pri zdravih prostovoljcih v stanju dinamičnega ravnovesja kažejo na to, da prihaja do dnevnih sprememb v farmakokinetiki indinavirja.
Desiccant should not be removed from the container.
Sušilnega sredstva ne smete odstraniti iz vsebnika.
Other medicines and CRIXIVAN
Druga zdravila in zdravilo CRIXIVAN
If no alternative treatment is available, use with careful monitoring.
Če drugo zdravljenje ni na voljo, skrbno spremljajte potek.
At least eleven amino acid sites in the protease have been associated with indinavir resistance: L10, K20, L24, M46, I54, L63, I64, A71, V82, I84, and L90.
Odkrili so najmanj enajst aminokislinskih mest na proteazi, ki so povezana z rezistenco na indinavir: L10, K20, L24, M46, I54, L63, I64, A71, V82, I84 in L90.
In rats and rabbits, no effects on embryonic/foetal survival or foetal weights were observed.
Pri podganah in kuncih niso opazili nobenih učinkov na embrionalno/fetalno preživetje ali na maso ploda.
The risk of you having bone problems is higher if you: - drink alcohol - have a high body mass index - have an immune system that is very weak - have been taking corticosteroids at the same time as CRIXIVAN - take combination antiretroviral therapy for a long time.
Tveganje, da boste imeli težave s kostmi, je večja, če: - pijete alkohol - imate visok indeks telesne mase - imate zelo oslabljen imunski sistem - ste prejemali kortikosteroide istočasno z zdravilom CRIXIVAN - ste dalj časa na kombiniranem protiretrovirusnem zdravljenju
• The active substance is indinavir.
• Zdravilna učinkovina je indinavir.
• Do not crush or chew the capsules.
• Kapsul ne drobite ali žvečite.
• feeling dizzy, weak or tired.
• občutek vrtoglavice, oslabelost ali utrujenost
• midazolam (by injection) - used for acute fits (seizures) and to send patients to sleep before some medical procedures
• midazolam (dan z injekcijo) - za zdravljenje akutnih napadov krčev in uspavanje bolnikov pred nekaterimi medicinskimi posegi
Tell your doctor, pharmacist or nurse if you are taking, have recently taken, or might take any other medicines.
Obvestite svojega zdravnika, farmacevta ali medicinsko sestro, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
In addition, when CRIXIVAN is given at the same time as the medicine ritonavir: Do not take either CRIXIVAN or ritonavir:
Poleg tega, ko zdravilo CRIXIVAN jemljete istočasno kot zdravilo ritonavir: Ne jemljite niti zdravila CRIXIVAN niti ritonavirja:
Most patients continued treatment with CRIXIVAN without dose reduction and bilirubin values gradually declined toward baseline.
Večina bolnikov je nadaljevala z zdravljenjem z zdravilom CRIXIVAN, ne da bi jim zmanjšali odmerek, koncentracija bilirubina pa se je počasi zmanjševala proti osnovni vrednosti.
No formal interaction study has been performed.
Uradnih študij medsebojnega delovanja niso izvedli.
It should be noted that the decrease in suppression of viral RNA levels was seen more frequently when therapy with indinavir was initiated at doses lower than the recommended oral dose of 2.4 g/day.
Treba je opozoriti še na to, da je do zmanjšanja supresije ravni virusne RNA prišlo pogosteje, kadar so zdravljenje z indinavirjem začeli z odmerki, nižjimi od priporočenega peroralnega odmerka 2,4 g na dan.
The resulting immature particles are noninfectious and are incapable of establishing new cycles of infection.
Nastanejo nezreli virusni delci, ki niso kužni in ne morejo začeti novega kroga okužbe.
Studies in rats indicated that uptake into brain tissue was limited, distribution into and out of the lymphatic system was rapid, and excretion into the milk of lactating rats was extensive.
Raziskave pri podganah so pokazale omejen privzem v možgane, hitro porazdelitev v limfatični sistem in iz njega ter obsežno izločanje v mleko doječih podgan.
The observed amino acid substitutions appeared to accumulate sequentially and in no consistent order, probably as a result of ongoing viral replication.
Zdelo se je, da se aminokislinske substitucije kopičijo zaporedno in brez doslednega reda, verjetno zaradi stalno potekajočega virusnega podvajanja.
Dose adjustment should be considered based on the patient's clinical response to methadone therapy.
O prilagoditvi odmerka je treba razmisliti glede na bolnikov klinični odziv na zdravljenje z metadonom.
Formulation with buffer
Formulacija s pufrom
Developmental toxicity studies were performed in rats, rabbits and dogs (at doses which produced systemic exposures comparable to or slightly greater than human exposure) and revealed no evidence of teratogenicity.
Raziskave o toksičnih učinkih na razvoj so opravili na podganah, kuncih in psih (z odmerki, ki povzročijo sistemsko izpostavljenost, primerljivo ali rahlo večjo od izpostavljenosti pri človeku) in niso odkrili dokazov za teratogenost.
There is no significant effect of unboosted indinavir on methadone AUC (see Table 1 above).
Pomembnega učinka neokrepljenega indinavirja na AUC metadona ni (glejte zgornjo tabelo 1).
To ensure adequate hydration, it is recommended that adults drink at least 1.5 litres of liquids during the course of 24 hours.
Za zagotovitev zadostne količine vode v telesu priporočamo, da odrasel bolnik v 24-ih urah popije vsaj 1,5 l tekočine.
• severe skin reactions
• hude kožne reakcije
CRIXIVAN can affect the way some other medicines work.
Zdravilo CRIXIVAN lahko vpliva na delovanje drugih zdravil.
Indinavir did not significantly inhibit the eukaryotic proteases human renin, human cathepsin D, human elastase, and human factor Xa.
Indinavir ni pomembno inhibiral evkariontskih proteaz: humanega renina, humanega katepsina D, humane elastaze in humanega faktorja Xa.
What CRIXIVAN is and what it is used for
Kaj je zdravilo CRIXIVAN in za kaj ga uporabljamo
Many of the protease amino acid substitutions reported to be associated with resistance to ritonavir and saquinavir were also associated with resistance to indinavir.
Veliko proteaznih aminokislinskih substitucij, o katerih so poročali, da so povezane z rezistenco na ritonavir in sakvinavir, je bilo povezanih tudi z rezistenco na indinavir.
The safety and efficacy of CRIXIVAN in children under the age of 4 years have not been established (see sections 5.1 and 5.2).
Varnost in učinkovitost zdravila CRIXIVAN pri otrocih, mlajših od 4 let, nista bili dokazani (glejte poglavji 5.1 in 5.2).
Atazanavir as well as indinavir are associated with indirect (unconjugated) hyperbilirubinemia due to inhibition of UDP-glucuronosyltransferase (UGT).
Atazanavir kot tudi indinavir sta povezana z indirektno (nekonjugirano) hiperbilirubinemijo zaradi inhibicije UDP-glukuronoziltransferaze (UGT).
• It is important for adults to drink at least 1.5 litres of liquid each day while taking CRIXIVAN.
• Za odrasle je pomembno, da med jemanjem zdravila CRIXIVAN vsak dan popijejo vsaj
Asymptomatic pyuria of unknown etiology was noted in 10.9 % (6/55) of paediatric patients who received CRIXIVAN.
Asimptomatsko piurijo neznanega izvora so opazili pri 10,9 % (6/55) pediatričnih bolnikov, ki so prejemali zdravilo CRIXIVAN.
Do not take CRIXIVAN if you are taking or have recently taken any of these medicines.
Ne jemljite zdravila CRIXIVAN, če jemljete ali ste pred kratkim jemali katero koli od naštetih zdravil.
The combination of trazodone with indinavir/ritonavir should be used with caution, initiating trazodone at the lowest dose and monitoring for clinical response and tolerability.
Kombinacijo trazodona in indinavirja/ritonavirja je treba uporabljati previdno, pri čemer je treba terapijo s trazodonom začeti z najmanjšim odmerkom ter spremljati klinični odziv in toleranco.
The suggestion is based on limited published data (see section 5.2).
To temelji na omejenih objavljenih podatkih (glejte poglavje 5.2).
The recommended dose of CRIXIVAN is:
Priporočeni odmerek zdravila CRIXIVAN je:
The design of the study does not allow for definitive evaluation of the effect of saquinavir on indinavir, but suggests there is less than a two-fold increase in indinavir AUC8h during co-administration with saquinavir
Oblika študije ne omogoča natančne ocene učinka sakvinavirja na indinavir, vendar pa kaže, da se med sočasnim dajanjem s sakvinavirjem pojavi manj kot dvakratno povečanje AUC8h indinavirja.
• If this happens, your treatment will stop working.
• V tem primeru bo zdravljenje s tem zdravilom postalo neučinkovito.
For information regarding diet or the effect of food on indinavir absorption (see sections 4.2 and 5.2).
(Za informacije glede diete ali vpliva hrane na absorpcijo indinavirja glejte poglavji 4.2 in 5.2).
When loss of viral RNA suppression occurred, it was typically associated with replacement of circulating susceptible virus with resistant viral variants.
Kadar je prišlo do izgube supresije virusne RNA, je bilo to ponavadi povezano z zamenjavo cirkulirajočega občutljivega virusa z rezistentno virusno različico.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
V primeru sočasnega zdravljenja hepatitisa B ali C z drugimi protivirusnimi zdravili, prosimo, preberite ustrezno navodilo za uporabo teh zdravil.
PDE5 INHIBITOR Sildenafil, tadalafil
ZAVIRALEC PDE5 Sildenafil, tadalafil
Given that substantially lower antepartum exposures have been observed in a small study of HIV-infected pregnant patients and the limited data in this patient population, indinavir use is not recommended in HIV-infected pregnant patients (see section 5.2).
Glede na to, da so v majhni raziskavi nosečih žensk, okuženih s HIV, opazovali znatno manjšo predporodno izpostavljenost, in glede na omejene podatke pri tej populaciji bolnic, uporabe indinavira pri nosečih ženskah, okuženih s HIV, ne priporočamo (glejte poglavje 5.2).
Therefore, therapy with indinavir should be initiated at the recommended dose to increase suppression of viral replication and therefore inhibit the emergence of resistant virus.
Zato je zdravljenje z indinavirjem treba začeti s priporočenim odmerkom, da bi se povečala supresija virusnega podvajanja in tako preprečil pojav rezistentnega virusa.
Because it is unknown whether indinavir will exacerbate physiologic hyperbilirubinaemia in neonates, careful consideration must be given to the use of indinavir in pregnant women at the time of delivery (see section 4.8).
Ker ni znano, če indinavir poslabša fiziološko hiperbilirubinemijo pri novorojenčkih, je treba skrbno pretehtati uporabo indinavirja pri nosečnicah v času poroda (glejte poglavje 4.8).
• If you are also taking ritonavir, then you can take CRIXIVAN at any time of the day with or without food.
• Če jemljete tudi ritonavir, lahko vzamete zdravilo CRIXIVAN kadar koli v dnevu z ali brez hrane.
See your doctor straight away if you notice any of the following serious side effects - you may need urgent medical treatment:
Če opazite katerega koli od naslednjih resnih neželenih učinkov, se nemudoma posvetujte z zdravnikom - morda boste potrebovali nujno zdravljenje:
ANTICOAGULANT Warfarin
ANTIKOAGULANT Varfarin
How CRIXIVAN works CRIXIVAN treats HIV and helps to lower the number of HIV particles in your blood.
Kako zdravilo CRIXIVAN deluje Zdravilo CRIXIVAN zdravi okužbo s HIV in pomaga zmanjšati število HIV delcev v vaši krvi.
Pharmacotherapeutic group: Antivirals for systemic use, protease inhibitor, ATC code JO5AE02
Farmakoterapevtska skupina: Zdravila za sistemsko zdravljenje virusnih infekcij, zaviralec proteaze, Oznaka ATC: JO5AE02
Such problems might be due to a bone disease called ‘osteonecrosis' (loss of blood supply to the bone causing bone death), which can occur months to years after starting HIV therapy.
Take težave lahko povzročijo bolezen kosti, imenovana 'osteonekroza' (odmiranje kosti zaradi nezadostne prekrvavitve kosti), ki se lahko pojavi več mesecev ali let po začetku zdravljenja okužbe z virusom HIV.
• Take this medicine by mouth.
• Vzemite skozi usta.
Mean urinary excretion of unchanged medicinal product following single dose administration in the fasted state was 10.4 % following a 700-mg dose, and 12.0 % following a 1,000-mg dose.
Povprečen delež izločanja nespremenjenega zdravila v urinu po enkratnem odmerku na tešče je znašal 10,4 % po 700 mg in 12,0 % po 1000 mg odmerku.
Six of these 11 (55 %) patients had mean indinavir plasma concentrations 8 hours postdose (Cmin) below assay threshold of reliable quantification.
Šest preiskovank med temi 11 (55 %) je imelo povprečno plazemsko koncentracijo indinavirja 8 ur po odmerku (cmin) nižjo od praga zanesljive kvantitativne določitve pri testu.
Loss of suppression of viral RNA levels occurred in some patients; however, CD4 cell counts were often sustained above pre-treatment levels.
Pri nekaterih bolnikih je prišlo do izgube supresije ravni virusne RNA, vendar pa je število CD4 celic pogosto ostalo višje, kot je bilo pred zdravljenjem.
• sildenafil, vardenafil, tadalafil - used for impotence
• sildenafil, vardenafil, tadalafil - za impotenco
Caution is warranted and clinical monitoring of patients is recommended.
Priporočata se previdnost in klinično spremljanje bolnikov.
The following effects may happen:
Pojavijo se lahko naslednji simptomi:
The recommendation is based on limited pharmacokinetic data (see section 5.2).
Priporočilo temelji na omejenih farmakokinetičnih podatkih (glejte poglavje 5.2).
Renal clearance (116 mL/min) of indinavir is concentration-independent over the clinical dose range.
Ledvični očistek indinavirja (116 ml/min) je v kliničnem odmernem območju neodvisen od koncentracije.
CRIXIVAN is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults.
Zdravilo CRIXIVAN je v kombinaciji s protiretrovirusnimi nukleozidnimi analogi indicirano za zdravljenje z virusom HIV-1 okuženih odraslih.
Caution is advised.
Potrebna je previdnost.
Resistance was correlated with the accumulation of mutations in the viral genome that resulted in the expression of amino acid substitutions in the viral protease.
Rezistenca je bila povezana s kopičenjem mutacij v virusnem genomu, kar je povzročilo ekspresijo aminokislinskih substitucij v virusni proteazi.
Also some other medicines can affect the way CRIXIVAN works.
Prav tako druga zdravila lahko vplivajo na delovanje zdravila CRIXIVAN.
It is recommended that HIV infected women do not breast feed their infants under any circumstances in order to avoid transmission of HIV.
Priporočeno je, naj ženske okužene z virusom HIV nikakor ne dojijo, da bi se izognile prenosu virusa HIV na novorojenčka.
Crixivan, 800 mg every 8 hours + zidovudine 200 mg every 8 hours and lamivudine 150 mg twice a day).
CRIXIVAN, 800 mg vsakih 8 ur + zidovudin 200 mg vsakih 8 ur in lamivudin 150 mg dvakrat na dan).
• warfarin - used to thin the blood
• varfarin - za redčenje krvi
• atorvastatin, rosuvastatin, pravastatin, fluvastatin - used to lower cholesterol
• atorvastatin, rosuvastatin, pravastatin, fluvastatin - za zniževanje holesterola
Thirty subjects completed 48 weeks of treatment.
48-tedensko zdravljenje je zaključilo trideset preizkušancev.
• autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection.
• avtoimune bolezni (stanje, ko imunski sistem napade zdravo telesno tkivo) se lahko pojavijo po začetku jemanja zdravil za zdravljenje okužbe z virusom HIV.
In addition, talk to your doctor, pharmacist or nurse before taking CRIXIVAN if you are taking any of the following medicines since your doctor may want to adjust the dose of your medicines:
Poleg tega se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden vzamete zdravilo CRIXIVAN, če jemljete katero od naslednjih zdravil, saj vam bo zdravnik morda prilagodil odmerek zdravil:
If you notice any symptoms of infection, please inform your doctor immediately.
Če opazite kakršne koli znake okužbe, takoj obvestite zdravnika.
However, patients should be informed that dizziness and blurred vision have been reported during treatment with indinavir.
Bolnike pa je treba opozoriti na to, da so med zdravljenjem z indinavirjem poročali o omotici in zamegljenem vidu.
• kidney problems (including inflammation of the kidneys, kidney stones, or back pain with or without blood in your urine)
• težave z ledvicami (vključno z vnetjem ledvic, ledvičnimi kamni ali bolečinami v hrbtu z ali brez krvi v urinu)
In patients at increased risk, urinary screening should be considered.
Pri bolj ogroženih bolnikih so potrebne preiskave urina.
In vitro studies with human liver microsomes indicated that CYP3A4 is the only P450 isozyme that plays a major role in the oxidative metabolism of indinavir.
In vitro raziskave s človeškimi jetrnimi mikrosomi so pokazale, da je CYP3A4 edini P450 izoencim, ki igra pomembno vlogo v oksidativnem metabolizmu indinavirja.
As a result of the short half-life, 1.8 ± 0.4 hours, only a minimal increase in plasma concentrations occurred after multiple dosing.
Zaradi kratkega razpolovnega časa (1,8  0,4 ure) je po večkratnem odmerjanju prišlo le do minimalnega porasta plazemske koncentracije.
This overall safety profile remained similar for 107 patients treated with CRIXIVAN monotherapy or in combination with NRTI(s) for up to 48 weeks.
Ta celotni varnostni profil je ostal enak pri 107-ih bolnikih, ki so se do 48 tednov zdravili z zdravilom CRIXIVAN samim ali v kombinaciji z NRTI.
Indinavir did not alter the type, frequency, or severity of known major adverse effects associated with the use of zidovudine, didanosine, or lamivudine.
Uporaba indinavirja ni spremenila tipa, pogostnosti ali resnosti znanih glavnih neželenih učinkov, povezanih z uporabo zidovudina, didanozina ali lamivudina.
Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART).
Čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredovalo boleznijo HIV in/ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART - combination antiretroviral therapy).
Combination contraindicated due to an increased risk of myopathy including rhabdomyolysis.
Kombinacija je kontraindicirana zaradi povečanega tveganja za miopatijo, vključno z rabdomiolizo.
• This is because reducing or missing doses will make it more likely that HIV will become resistant to CRIXIVAN.
• Z zmanjšanjem ali izpustitvijo odmerka se bo povečalo tveganje, da virus HIV postane odporen na zdravilo CRIXIVAN.
Following initiation of indinavir/ritonavir 800/100 BID or lopinavir/ritonavir 400/100 BID, dose reduction of cyclosporine A to 5-20 % of prior dose was needed to maintain cyclosporine A levels within therapeutic range in one study.
Po začetku dajanja indinavirja/ritonavirja 800/100 BID ali lopinavirja/ritonavirja 400/100 BID so morali v eni študiji odmerek ciklosporina A zmanjšati za 5-20 %, da se je raven ciklosporina A vzdrževala v terapevtskem razponu.
What you need to know before you take CRIXIVAN
Kaj morate vedeti, preden boste vzeli zdravilo CRIXIVAN
Complete cross resistance was noted between indinavir and ritonavir; however, cross resistance to saquinavir varied among isolates.
Popolno navzkrižno rezistenco so ugotovili med indinavirjem in ritonavirjem; stopnja navzkrižne rezistence s sakvinavirom pa se je med izolati spreminjala.